Portal de Periódicos da CAPES

Whole genome sequencing for the genetic diagnosis of heterogenous dystonia phenotypes

2019; Elsevier BV; Volume: 69; Linguagem: Inglês

10.1016/j.parkreldis.2019.11.004

1873-5126

Kishore R. Kumar, Ryan L. Davis, Michel Tchan, Gautam Wali, Neil Mahant, Karl Ng, Katya Kotschet, Sue-Faye Siow, Jason Gu, Zachary F. Walls, Ce Kang, Gautam Wali, Stan Levy, Chun Seng Phua, Con Yiannikas, Paul Darveniza, Florence Chang, Hugo Morales‐Briceño, Dominic B. Rowe, Alexander P. Drew, Velimir Gayevskiy, Mark J. Cowley, André E. Minoche, Stephen Tisch, Mike Hayes, Sarah Kummerfeld, Victor S.C. Fung, Carolyn M. Sue,

Genetics and Neurodevelopmental Disorders

Dystonia is a clinically and genetically heterogeneous disorder and a genetic cause is often difficult to elucidate. This is the first study to use whole genome sequencing (WGS) to investigate dystonia in a large sample of affected individuals.WGS was performed on 111 probands with heterogenous dystonia phenotypes. We performed analysis for coding and non-coding variants, copy number variants (CNVs), and structural variants (SVs). We assessed for an association between dystonia and 10 known dystonia risk variants.A genetic diagnosis was obtained for 11.7% (13/111) of individuals. We found that a genetic diagnosis was more likely in those with an earlier age at onset, younger age at testing, and a combined dystonia phenotype. We identified pathogenic/likely-pathogenic variants in ADCY5 (n = 1), ATM (n = 1), GNAL (n = 2), GLB1 (n = 1), KMT2B (n = 2), PRKN (n = 2), PRRT2 (n = 1), SGCE (n = 2), and THAP1 (n = 1). CNVs were detected in 3 individuals. We found an association between the known risk variant ARSG rs11655081 and dystonia (p = 0.003).A genetic diagnosis was found in 11.7% of individuals with dystonia. The diagnostic yield was higher in those with an earlier age of onset, younger age at testing, and a combined dystonia phenotype. WGS may be particularly relevant for dystonia given that it allows for the detection of CNVs, which accounted for 23% of the genetically diagnosed cases.